$SBFM
Sunshine Biopharma Inc. Stock $sbfm

$sbfm Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000168316822007290 Filed on November 07, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$3.940M	$132.8K	$50.38K
YoY Change	4528.57%	163.61%	193.76%
Cost Of Revenue	$2.449M	$65.78K	$19.51K
YoY Change	3895.3%	237.18%	207.73%
Gross Profit	$1.491M	$67.03K	$30.87K
YoY Change	6157.32%	117.12%	185.57%
Gross Profit Margin	37.85%	50.47%	61.27%
Selling, General & Admin	$6.305M	$1.422M	$301.5K
YoY Change	2915.46%	371.58%	304.29%
% of Gross Profit	422.82%	2121.18%	976.61%
Research & Development	$41.76K	$362.5K	$222.5K
YoY Change	-54.21%	62.94%
% of Gross Profit	2.8%	540.84%	720.67%
Depreciation & Amortization	$18.97K	$789.00	$3.190K
YoY Change	496.54%	-75.27%	-9.12%
% of Gross Profit	1.27%	1.18%	10.33%
Operating Expenses	$6.528M	$362.5K	$527.1K
YoY Change	2051.19%	-31.23%	575.03%
Operating Profit	-$5.037M	-$1.718M	-$496.3K
YoY Change	1701.27%	246.19%	637.6%
Interest Expense	$84.60K	$2.00	-$46.81K
YoY Change	-394.77%	-100.0%	97.59%
% of Operating Profit
Other Income/Expense, Net		$261.0K	$0.00
YoY Change
Pretax Income	-$23.28M	-$1.457M	-$4.039M
YoY Change	-3589.48%	-63.93%	478.21%
Income Tax	$233.3K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$23.51M	-$1.457M	-$4.039M
YoY Change	-3624.45%	-63.93%	478.21%
Net Earnings / Revenue	-596.78%	-1097.09%	-8017.82%
Basic Earnings Per Share		-$0.08	-$1.59
Diluted Earnings Per Share	-$1.05	-$77.15K	-$1.589M
COMMON SHARES
Basic Shares Outstanding	22.59M shares	18.89M shares	2.543M shares
Diluted Shares Outstanding		18.89M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.83M	$40.56M	$2.387M
YoY Change	967.22%	1599.31%	388.35%
Cash & Equivalents	$21.83M	$40.56M	$2.387M
Short-Term Investments
Other Short-Term Assets	$283.8K	$34.98K	$32.64K
YoY Change	662.49%	7.17%	157.01%
Inventory	$3.290M	$269.6K	$71.31K
Prepaid Expenses	$283.8K	$27.39K
Receivables	$1.912M	$22.00	$1.130K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.31M	$40.86M	$2.492M
YoY Change	1143.83%	1539.88%	372.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$394.2K	$3.770K	$10.23K
YoY Change	5483.47%	-63.15%	-55.37%
Goodwill	$0.00
YoY Change
Intangibles	$776.9K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.932M	$3.770K	$10.24K
YoY Change	27254.68%	-63.18%	-55.32%
TOTAL ASSETS
Total Short-Term Assets	$27.31M	$40.86M	$2.492M
Total Long-Term Assets	$1.932M	$3.770K	$10.24K
Total Assets	$29.24M	$40.86M	$2.502M
YoY Change	1227.52%	1533.32%	354.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.803M	$480.2K	$56.69K
YoY Change	6426.93%	747.08%	-1.73%
Accrued Expenses	$123.0K	$0.00	$84.95K
YoY Change	154.77%	-100.0%	168.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$0.00		$330.0K
YoY Change			-37.76%
Total Short-Term Liabilities	$6.931M	$480.2K	$471.6K
YoY Change	7497.38%	1.82%	-36.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$3.204M
YoY Change	-100.0%	-100.0%	796.16%
Other Long-Term Liabilities	$642.2K
YoY Change
Total Long-Term Liabilities	$685.3K	$0.00	$3.204M
YoY Change	-63.93%	-100.0%	796.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.931M	$480.2K	$471.6K
Total Long-Term Liabilities	$685.3K	$0.00	$3.204M
Total Liabilities	$7.616M	$480.2K	$3.676M
YoY Change	282.49%	-86.94%	232.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$59.40M	-$35.89M
YoY Change	81.9%
Common Stock	$22.59K	$18.89K
YoY Change	771.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.63M	$40.38M	-$1.174M
YoY Change
Total Liabilities & Shareholders Equity	$29.24M	$40.86M	$2.502M
YoY Change	1227.52%	1533.32%	354.46%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$23.51M	-$1.457M	-$4.039M
YoY Change	-3624.45%	-63.93%	478.21%
Depreciation, Depletion And Amortization	$18.97K	$789.00	$3.190K
YoY Change	496.54%	-75.27%	-9.12%
Cash From Operating Activities	-$2.247M	-$1.124M	-$600.8K
YoY Change	619.81%	87.04%	398.27%
INVESTING ACTIVITIES
Capital Expenditures	$305.0K		$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$14.31M
YoY Change
Cash From Investing Activities	-$14.62M		$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.096M	0.000	1.276M
YoY Change	8759.89%	-100.0%	143.16%
NET CHANGE
Cash From Operating Activities	-2.247M	-1.124M	-600.8K
Cash From Investing Activities	-14.62M		0.000
Cash From Financing Activities	-2.096M	0.000	1.276M
Net Change In Cash	-18.96M	-1.124M	674.9K
YoY Change	5547.39%	-266.51%	67.36%
FREE CASH FLOW
Cash From Operating Activities	-$2.247M	-$1.124M	-$600.8K
Capital Expenditures	$305.0K		$0.00
Free Cash Flow	-$2.552M		-$600.8K
YoY Change	717.54%		401.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001402328
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41282
	dei	Entity Registrant Name EntityRegistrantName	SUNSHINE BIOPHARMA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5566275
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6500 Trans-Canada Highway
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40555931	usd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	4th Floor
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Pointe-Claire
	dei	Entity Address City Or Town EntityAddressCityOrTown	Quebec
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	H9R 0A5
	dei	City Area Code CityAreaCode	(514)
	dei	Local Phone Number LocalPhoneNumber	426-6161
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22585632	shares
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2045167	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7798	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	269641	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	105650	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	27390	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	29625	usd
CY2022Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	7590	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	7590	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	40860574	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2195830	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3770	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7061	usd
CY2022Q3	us-gaap	Assets Assets	40864344	usd
CY2021Q4	us-gaap	Assets Assets	2202891	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	480209	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	42942	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	48287	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	480209	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	91229	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1900000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	480209	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1991229	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	100000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18885632	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18885632	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2591240	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2591240	shares
CY2021Q3	us-gaap	Revenues Revenues	50376	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	18886	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2591	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	76331451	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	32787384	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-79903	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23139	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35887299	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32655174	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	40384135	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	211662	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40864344	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2202891	usd
CY2022Q3	us-gaap	Revenues Revenues	132808	usd
	us-gaap	Revenues Revenues	405760	usd
	us-gaap	Revenues Revenues	143308	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	65783	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	19506	usd
	us-gaap	Cost Of Revenue CostOfRevenue	200311	usd
	us-gaap	Cost Of Revenue CostOfRevenue	56541	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	67025	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	30870	usd
	us-gaap	Gross Profit GrossProfit	205449	usd
	us-gaap	Gross Profit GrossProfit	86767	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	122913	usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	35000	usd
	us-gaap	Professional Fees ProfessionalFees	237773	usd
	us-gaap	Professional Fees ProfessionalFees	96200	usd
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	217666	usd
CY2021Q3	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	us-gaap	Advertising Expense AdvertisingExpense	400386	usd
	us-gaap	Advertising Expense AdvertisingExpense	0	usd
CY2022Q3	SBFM	Consulting Expense ConsultingExpense	162852	usd
CY2021Q3	SBFM	Consulting Expense ConsultingExpense	20598	usd
	SBFM	Consulting Expense ConsultingExpense	270033	usd
	SBFM	Consulting Expense ConsultingExpense	53168	usd
CY2022Q3	us-gaap	Legal Fees LegalFees	142883	usd
CY2021Q3	us-gaap	Legal Fees LegalFees	56923	usd
	us-gaap	Legal Fees LegalFees	388238	usd
	us-gaap	Legal Fees LegalFees	159074	usd
CY2022Q3	SBFM	Office Expense OfficeExpense	76818	usd
CY2021Q3	SBFM	Office Expense OfficeExpense	58959	usd
	SBFM	Office Expense OfficeExpense	449730	usd
	SBFM	Office Expense OfficeExpense	159762	usd
CY2022Q3	SBFM	Officer And Director Remuneration OfficerAndDirectorRemuneration	695000	usd
CY2021Q3	SBFM	Officer And Director Remuneration OfficerAndDirectorRemuneration	130000	usd
	SBFM	Officer And Director Remuneration OfficerAndDirectorRemuneration	1305000	usd
	SBFM	Officer And Director Remuneration OfficerAndDirectorRemuneration	1173927	usd
CY2022Q3	SBFM	Patenting Fees PatentingFees	3584	usd
CY2021Q3	SBFM	Patenting Fees PatentingFees	1	usd
	SBFM	Patenting Fees PatentingFees	15148	usd
	SBFM	Patenting Fees PatentingFees	14571	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	362500	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	222465	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	770095	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	581011	usd
CY2022Q3	us-gaap	Depreciation Depreciation	789	usd
CY2021Q3	us-gaap	Depreciation Depreciation	3183	usd
	us-gaap	Depreciation Depreciation	6186	usd
	us-gaap	Depreciation Depreciation	9557	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1785005	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	527129	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3842589	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2247270	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1717980	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-496259	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3637140	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2160503	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	25	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	37	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	45	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	31	usd
CY2022Q3	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	260938	usd
CY2021Q3	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	0	usd
	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	406984	usd
	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	0	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	2	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	46849	usd
	us-gaap	Interest Expense InterestExpense	12866	usd
	us-gaap	Interest Expense InterestExpense	292188	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	7688	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10852	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	58940	usd
CY2022Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	-0	usd
CY2021Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	3504000	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	-0	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	10709843	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	260961	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3543124	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	405015	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1457019	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4039383	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3232125	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13103563	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-45126	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-5839	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10943060	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1457019	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-4039383	usd
	us-gaap	Profit Loss ProfitLoss	-3232125	usd
	us-gaap	Profit Loss ProfitLoss	-13103563	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-56764	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-14604	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1502145	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4045222	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3288889	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13118167	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.73
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18885632	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2542640	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12789733	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2287682	shares
	us-gaap	Profit Loss ProfitLoss	-3232125	usd
	us-gaap	Profit Loss ProfitLoss	-13103563	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6186	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9557	usd
	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-45	usd
	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	31	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	918000	usd
	SBFM	Stock Issued For Payment Interest On Notes Payable StockIssuedForPaymentInterestOnNotesPayable	0	usd
	SBFM	Stock Issued For Payment Interest On Notes Payable StockIssuedForPaymentInterestOnNotesPayable	38201	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	10709843	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10852	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	58940	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7776	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-787	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	163991	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	47539	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2235	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	22268	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	437267	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-13778	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-48287	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	52716	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3001746	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1517015	usd
	SBFM	Proceeds Public Offering Net ProceedsPublicOfferingNet	-43560363	usd
	SBFM	Proceeds Public Offering Net ProceedsPublicOfferingNet	-3318500	usd
	SBFM	Redemption Or Proceeds From Preferred Shares RedemptionOrProceedsFromPreferredShares	-99000	usd
	SBFM	Redemption Or Proceeds From Preferred Shares RedemptionOrProceedsFromPreferredShares	61500	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1900000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	451661	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41561363	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2928339	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2045167	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	989888	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	38559617	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1411324	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-105617	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56764	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-14604	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40555931	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2386608	usd
	SBFM	Stock Issued For Note Conversions Including Interest StockIssuedForNoteConversionsIncludingInterest	0	usd
	SBFM	Stock Issued For Note Conversions Including Interest StockIssuedForNoteConversionsIncludingInterest	11981072	usd
	us-gaap	Interest Paid Net InterestPaidNet	61151	usd
	us-gaap	Interest Paid Net InterestPaidNet	155081	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	41886280	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1502145	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	40384135	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	211662	usd
	SBFM	Common Stock And Prefunded Warrants Issued In Underwrittenpublic And Private Offerings Net Of Issuance Costs CommonStockAndPrefundedWarrantsIssuedInUnderwrittenpublicAndPrivateOfferingsNetOfIssuanceCosts	30367185	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13193177	usd
	SBFM	Preferred Stock Purchased From Related Party Value PreferredStockPurchasedFromRelatedPartyValue	99000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3288889	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	40384135	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-872710	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3744000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4045222	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1173932	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-954837	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	11981072	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	918000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13118167	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1173932	usd
CY2022Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	990000	shares
CY2022Q3	us-gaap	Notes Payable NotesPayable	0	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	1900000	usd
CY2022Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0	usd
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	48287	usd
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6833071	usd
	us-gaap	Dividends Dividends	0	usd
CY2022Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	595000	usd
CY2021Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	105000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1095000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	130000	usd
CY2022Q3	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	100000	usd
CY2021Q3	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	200000	usd
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	200000	usd

Files In Submission

Name	View Source	Status
0001683168-22-007290-index-headers.html	Edgar Link	pending
0001683168-22-007290-index.html	Edgar Link	pending
0001683168-22-007290.txt	Edgar Link	pending
0001683168-22-007290-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
s1.jpg	Edgar Link	pending
s2.jpg	Edgar Link	pending
s3.jpg	Edgar Link	pending
sbfm-20220930.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
sunshine_ex3101.htm	Edgar Link	pending
sunshine_ex3102.htm	Edgar Link	pending
sunshine_ex3201.htm	Edgar Link	pending
sunshine_i10q-093022.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
sbfm-20220930_cal.xml	Edgar Link	unprocessable
sbfm-20220930_def.xml	Edgar Link	unprocessable
sbfm-20220930_lab.xml	Edgar Link	unprocessable
sbfm-20220930_pre.xml	Edgar Link	unprocessable
sunshine_i10q-093022_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SBFM
Sunshine Biopharma Inc. Stock $sbfm

2022 Q4 Form 10-Q Financial Statement

#000168316822007290 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM Sunshine Biopharma Inc. Stock $sbfm

2022 Q4 Form 10-Q Financial Statement

#000168316822007290 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM
Sunshine Biopharma Inc. Stock $sbfm